Bivalirudin in percutaneous coronary intervention

Vascular Health and Risk Management

Volumn 2, Issue 4, 2006, Pages 357-363

  Lehman, Sam J ^a   Chew, Derek P ^a,b  

^a FLINDERS UNIVERSITY   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Acute coronary syndrome; Bivalirudin; Direct thrombin inhibitor; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATININE; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; THROMBOCYTE FACTOR 4; TIROFIBAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; BRACHYTHERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG COST; DRUG ELUTING STENT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HOLTER MONITORING; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; POSTOPERATIVE HEMORRHAGE; PROTEIN BINDING; PROTEIN SYNTHESIS INHIBITION; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL ISCHEMIA; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; RECURRENCE; SYNDROME; THROMBIN; THROMBOSIS;

EID: 33846913747     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: 10.2147/vhrm.2006.2.4.357     Document Type: Review

References (44)

1. Allie DE, Hebert CJ, Lirtzman MD, et al. 2005. A safety and feasibility report of combined direct thrombin and GP IIb/IIIa inhibition with bivalirudin and tirofiban in peripheral vascular disease intervention: treating critical limb ischemia like acute coronary syndrome. J Invasive Cardiol, 17:427-432.
2. Andersen DL, Greenberg, Fujikawa K, et al. 1999. Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity. Proc Nat. Acad Sci U S A, 96:11189-93.
3. Antman EM, McCabe CH, Braunwald E. 2002. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction. Am Heart J, 143:229-34.
4. Bates SM, Weitz JI. 2000. The mechanism of action of thrombin inhibitors. J Invasive Cardiol, 12(Suppl F): F27-32.
5. Becker RC. 2005. Understanding the dynamics of thrombin in cardiovascular disease: pathobiology and biochemistry for the clinician. Am Heart J, 149(Supp11):S2-8.
6. Bittl JA, Chaitmen BR, Feit F, et al. 2001. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplaaty Study. Am Heart J, 142:952-59.
7. Bittl JA, Strony J, Brinker JA, et al. 1995. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med, 333:764-769.
8. Brener SJ, Moliterno DJ, Lincoff AM, et al. 2004. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation, 110:994-8.
9. Chenean E, Canos D, Kuchulakanti PK, et al. 2004. Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneons coronary intervention. Am J Cardiol, 94:789-92.
10. Chew DP, Bhatt DL, Kimball W, et al. 2003. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol, 92:919-23.
11. Chew DP, Lincoff AM, Gurm H, et al. 2005. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol, 95:581-5.
12. Chong BH. 2003. Heparin-induced thrombocytopenia. J Thromb Haemost, 1:1471-8.
13. Cohen DJ, Lincoff AM, Lavelle TA, et al. 2004. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol, 44:1792-800.
14. Dangas G, Lasic Z, Mehran R, et al. 2005. Effectiveness of the concomitant use of bivalirudin and drug-eluting stents (from the prospective, multicenter BivAlirudin and Drug-Eluting STents [ADEST] study). Am J Cardiol, 96:659-63.
15. De Candia E, Hall SW, Rutella S, et al. 2001. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem, 276:4692-98.
16. Direct Thrombin Inhibitor Trialists' Collaborative Group. 2002. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet, 359:294-302.
17. Ebrahimi R, Lincoff AM, Bittl JA, et al. 2005. Bivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled Aualysis. J Cardiovasc Pharmacol Ther, 10:209-16.
18. Eitzman DT, Chi L, Saggin L, et al. 1994. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation, 89:1523-9.
19. Gibson CM, Morrow DA, Murphy SA, et al. 2006. A randomized trial to evaluate the relative protection against post-PCI microvascular dysfunction, ischaemia and inflammation among anti-platelet and antithrombotic agents: the PROTECT-TIMI 30 Trial. J Am Coll Cardiol, 47:2364-73.
20. Kuchulakanti P, Wolfram R, Torguson R, et al. 2005. Bivalirudin compared with IIb/IIIa inhibitors in patients with in-stent restenosis undergoing intracoronary brachytherapy. Cardiovasc Revasc Med, 6:154-9.
21. Lincoff AM, Bittl JA, Harrington RA. 2003. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA, 289:853-63.
22. Lincoff AM, Bittl JA, Kleiman NS, et al. 2004b. Comparison of Bivalirudin Versus Heparin During Percutaneous Coronary Intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 Trial. Am J Cardiol, 93:1092-6.
23. Lincoff AM, Kleiman NS, Kereiakes DJ, et al. 2004a. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA, 292:696-703.
24. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. 2002. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J, 143:847-53.
25. MacFarlane RG. 1964. An enzymatic cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature, 202:498-99.
26. Mahaffey KW, Lewis BE, Wildermann NM, et al. 2003. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol, 15:611-6.
27. Maraganore JM, Bourdon P, Jablonski J, et al. 1990. Design and characterization of hirulogs: a novel class of bivalant peptide inhibitors of thrombin. Biochemistry, 29:7095-101.
28. Parry MA, Maraganore JM, Stone SR. 1994. Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry, 33:14807-14.
29. Reed MD, Bell D. 2002. Clinical pharmacology of bivalirudin. Pharmacotherapy, 22:S105-11.
30. Robson R, White H, Aylward P, et al. 2002. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther, 71:433-9.
31. Sarich TC, Wolzt M, Eriksson UG, et al. 2003. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol, 41:557-64.
32. Saw J, Lincoff AM, DeSmet W, et al. 2004. Lack of clopidogrel pretreatment effect on the relative efficacy of Bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine giycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol, 44:1194-9.
33. Schussler JM, Cameron CS, Azam A, et al. 2004. Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide. Am J Cardiol, 94:1417-19.
34. Smith SC, Feldman TE, Hirshfeld JW et al. 2005. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention [online]. Accessed 25 Sept 2006. URL: http://www.acc.org.
35. Soslau G, Class R, Morgan DA, et al. 2001. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem, 276:21173-83.
36. Stone GW, Bertrand M, Colombo A, et al. 2004. Acute catheterization and urgent Intervention triage strategy (ACUITY) trial: study design and rationale. Am Heart J, 148:764-75.
37. Stone GW. 2006a. Prospective, Randomized Comparison of Heparin Plus IIb/ IIIa Inhibition and Bivalirudin With or Without IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes: The ACUITY Trial. American College of Cardiology Scientific Sessions 2006. Late Breaking Clinical Trials Session I.
38. Stone GW. 2006b. Prospective, Randomized Comparison of Routine Upfront Initiation Versus Selective Use of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes: The ACUITY Timing Trial. i2 Summit 2006 Late-Breaking Clinical Trials II.
39. Tulinsky A.1996. Molecular interactions of thrombin. Semin Thromb Hemost, 22:117-24.
40. Weitz JI, Hudoba M, Massel D, et al. 1990. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest, 86:385-91.
41. Weitz JI, Leslie B, Hudoba M. 1998. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation, 97:544-52.
42. White CM. 2005. Thrombin-directed inhibitors: pharmacology and clinical use. Am Heart J, 149:S54-60.
43. White H. 2001. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet, 358(9296):1855-63.
44. Xiao Z, Theroux P. 1998. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation, 97:251-6.